<DOC>
	<DOCNO>NCT01947790</DOCNO>
	<brief_summary>Cardiovascular complication account high mortality type 2 diabetic patient , mainly due ischeamia heart disease ( IHD ) . Most attention treat IHD type 2 diabetes understandably direct toward treat coronary artery condition . However treatable culprit patient . Left ventricular hypertrophy ( LVH ) widespread type 2 diabetic patient IHD , even absence hypertension . It strong predictor cardiovascular event all-cause mortality . In one study , presence LVH strong predictor mortality either multivessel coronary disease impair leave ventricular function . Regression LVH associate improved prognosis , independent change blood pressure ( BP ) . Therefore , cardiovascular event mortality type 2 diabetes IHD might reduce find novel therapy regress LVH . Pioglitazone improve atherosclerosis . Therefore , hypothesied pioglitazone regress leave ventricular mass ( LVM ) type 2 diabetes IHD.Therefore , study , treat patient pioglitazone , also metformin control .</brief_summary>
	<brief_title>Pioglitazone Regress Left Ventricular Mass Type 2 Diabetes With Ischeamia Heart Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>type 2 diabetes age 40ï½ž75 year old IHD heart failure renal failure hypertension ( &gt; 130/80 mmHg ) hemoglobin A1c 9 %</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>leave ventricular mass</keyword>
	<keyword>pioglitazone</keyword>
</DOC>